Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...

Earlier this month, Medtronic received a new approval from the FDA for its decades-old liquid embolic system, extending its ...

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...

After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...

Following years in development, the Finnish medtech GlucoModicum has unveiled its needle-free glucose monitoring patch, ...

A new mental health-driven biotech has arrived in Syremis Therapeutics. | Founded by a team of neuropsychiatric-focused Teva ...

The company rolled out Wi-Fi and 5G connectivity across its installed base of Maestro surgical robots, which it describes as ...